Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C35H43N7O11 |
| Molecular Weight | 737.7562 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@H](NC(=O)CCCCCN1C(=O)C=CC1=O)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC2=CC=C(COC(=O)OC3=CC=C(C=C3)[N+]([O-])=O)C=C2
InChI
InChIKey=HYSPJPGXSALJRR-DHIFEGFHSA-N
InChI=1S/C35H43N7O11/c1-22(2)31(40-28(43)8-4-3-5-20-41-29(44)17-18-30(41)45)33(47)39-27(7-6-19-37-34(36)48)32(46)38-24-11-9-23(10-12-24)21-52-35(49)53-26-15-13-25(14-16-26)42(50)51/h9-18,22,27,31H,3-8,19-21H2,1-2H3,(H,38,46)(H,39,47)(H,40,43)(H3,36,37,48)/t27-,31-/m0/s1
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. | 2002 Jul-Aug |
|
| Antineoplastic Agents. 605. Isoquinstatins. | 2018 Mar 23 |
|
| Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity. | 2019 Apr 1 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID101100278
Created by
admin on Sat Dec 16 19:16:18 GMT 2023 , Edited by admin on Sat Dec 16 19:16:18 GMT 2023
|
PRIMARY | |||
|
159857-81-5
Created by
admin on Sat Dec 16 19:16:18 GMT 2023 , Edited by admin on Sat Dec 16 19:16:18 GMT 2023
|
PRIMARY | |||
|
QY7B3AFP6T
Created by
admin on Sat Dec 16 19:16:18 GMT 2023 , Edited by admin on Sat Dec 16 19:16:18 GMT 2023
|
PRIMARY | |||
|
57587849
Created by
admin on Sat Dec 16 19:16:18 GMT 2023 , Edited by admin on Sat Dec 16 19:16:18 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
